You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Colorcon
AstraZeneca
Johnson and Johnson
Harvard Business School

Last Updated: October 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,709,022

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,709,022 protect, and when does it expire?

Patent 7,709,022 protects CIPRO XR and is included in one NDA.

Protection for CIPRO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-two patent family members in forty countries.

Summary for Patent: 7,709,022
Title:Sustained-release preparations of quinolone antibiotics and method for preparation thereof
Abstract:The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay.
Inventor(s): Kanikanti; Venkata-Rangarao (Leverkusen, DE), Rupp; Roland (Bergisch Gladbach, DE), Weber; Wolfgang (Koln, DE), Deuringer; Peter (Koln, DE), Henck; Jan-Olav (Willich, DE), Sta.beta.; Heino (Koln, DE), Nishioka; Takaaki (Nabari, JP), Katakawa; Yoshifumi (Kusatsu, JP), Taniguchi; Chika (Nishinomiya, JP), Ichihashi; Hitoshi (Suita, JP)
Assignee: Bayer Schering Pharma AG (Leverkussen, DE)
Application Number:10/311,913
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Drugs Protected by US Patent 7,709,022

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare CIPRO XR ciprofloxacin; ciprofloxacin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021473-001 Dec 13, 2002 DISCN No No   Start Trial   Start Trial Y   Start Trial
Bayer Hlthcare CIPRO XR ciprofloxacin; ciprofloxacin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021473-002 Aug 28, 2003 DISCN No No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,709,022

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany100 31 043Jun 26, 2000
PCT Information
PCT FiledJune 13, 2001PCT Application Number:PCT/EP01/06695
PCT Publication Date:January 03, 2002PCT Publication Number: WO02/00219

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Baxter
Dow
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.